Sagent Pharmaceuticals, Inc.
Schaumburg, IL Doing business as Sagent Pharmaceuticals, Inc.
- UEI
- PR1HCLM3FMW7
- CAGE
- 4RP13
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 1515 Woodfield Rd Suite 1100, Schaumburg, IL 60173, USA
- Website
- sagentpharma.com
- Founded
- 2007
- Employees
- 51-250
- Estimated annual revenue
- $250M-$500M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Ciprofloxaxin ivpb | Veterans Integrated Service Network 15 | $275,580 | |
| 4571894571 ! Levofloxacin 500 MG/100 ML-D5W 100ML | Medical Supply Chain | $48 | |
| 4571867271 ! Metronidazole 500 MG/100 ML 100ML | Medical Supply Chain | $13 | |
| 4571706829 ! Levofloxacin 500 MG/100 ML-D5W 100ML | Medical Supply Chain | $24 | |
| 4571632359 ! Levofloxacin 500 MG/100 ML-D5W 100ML | Medical Supply Chain | $24 |
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, Inc., a for-profit specialty pharmaceutical manufacturer headquartered in Schaumburg, Illinois, supplies injectable pharmaceutical products to the federal government as a prime contractor across multiple federal agencies and contract vehicles, competing on full-and-open merit with no set-aside designations across its entire federal footprint.
The company manufactures and delivers injectable medications—antibiotics (levofloxacin, ciprofloxacin, cefepime, ampicillin-sulbactam, metronidazole), anesthetics (propofol), and critical care products (adenosine)—primarily to defense and health agencies under firm fixed-price delivery orders. Recent representative work includes a $16.6 million delivery order from the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response for ciprofloxacin solution for injection (awarded September 2025), a $47.8 million strategic national stockpile contract from ASPR for ciprofloxacin 5% dextrose injection (awarded September 2022), and ongoing high-volume delivery orders from the Defense Logistics Agency Troop Support Medical for cefepime 2 gram solutions and other injectable antibiotics at unit values ranging from $24 to $22,080 per order.
Customer concentration is split between defense and civilian health agencies. The Defense Logistics Agency Troop Support Medical dominates by award count (293 awards, $69.5 million combined potential value) but not by dollars—civilian health programs anchor the largest single awards. The Department of Health and Human Services Centers for Disease Control and Prevention Pittsburgh ranks first by combined potential value at $158.5 million across nine awards. ASPR follows at $73.6 million across three awards, the VA at $26.4 million across ten awards, and CDC's Office of Acquisition Services at $135 thousand. Together, these five customer organizations account for 99% of awards and 100% of combined potential value.
Sagent maintains position on multiple contract vehicles. The company holds a $5.5 million Federal Supply Schedule contract with the Department of Veterans Affairs (FSS-61-IB, Pharmaceuticals and Drugs) running through April 30, 2029, awarded May 2024. It executes delivery orders against DLA indefinite delivery contracts: SPE2D021D0003 carries 206 task orders valued at $1.9 million combined and SPM2D013D0001 carries 86 task orders at $9.5 million combined. HHS vehicles include HHSD200201587789I (6 task orders, $43 million) and HHSD200201253681I (3 task orders, $135 thousand). These vehicles enable rapid procurement of injectable medications to military treatment facilities and federal civilian health programs.
Activity has remained relatively steady: 26 awards in 2022, 50 in 2023, 25 in 2024, 33 in 2025, and 26 in the first three months of 2026. The company carries a modest recompete cliff—two awards with ultimate completion dates in the next twenty-four months totaling $16.8 million combined potential value, representing minimal near-term recompete exposure. Across 320 prime awards tracked in the source, Sagent has obligated $142.8 million against a combined potential value of $330 million, a 43% utilization rate indicating substantial available capacity within existing vehicle ceilings. The company has not subcontracted on federal awards in the source data; 100% of tracked activity is prime.
Contract vehicles
Quick answers
What is Sagent Pharmaceuticals, Inc.'s UEI?
Sagent Pharmaceuticals, Inc.'s Unique Entity ID (UEI) in SAM.gov is PR1HCLM3FMW7.
What is Sagent Pharmaceuticals, Inc.'s CAGE code?
Sagent Pharmaceuticals, Inc.'s CAGE code is 4RP13.
What is Sagent Pharmaceuticals, Inc.'s primary NAICS code?
Sagent Pharmaceuticals, Inc.'s primary NAICS code is 325412 (Pharmaceutical Preparation Manufacturing).
Where is Sagent Pharmaceuticals, Inc. located?
Sagent Pharmaceuticals, Inc.'s physical address in SAM.gov is 1515 Woodfield Rd Suite 1100, Schaumburg, IL 60173, USA.
Is Sagent Pharmaceuticals, Inc. registered in SAM.gov?
Yes. Sagent Pharmaceuticals, Inc.'s SAM.gov registration is active through February 2, 2027.
Which contract vehicles does Sagent Pharmaceuticals, Inc. hold?
Sagent Pharmaceuticals, Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
What is Sagent Pharmaceuticals, Inc.'s most recent federal award?
Sagent Pharmaceuticals, Inc.'s most recent federal contract award is Ciprofloxaxin ivpb (36C77026P0086), from Veterans Integrated Service Network 15, on August 14, 2026.
On GovTribe
See Sagent Pharmaceuticals, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors